Elucidation of development and improvement of leptin resistance

与单独使用瘦素和exenlavin相比，联合使用瘦素和exenlavin可显著降低肥胖2型糖尿病小鼠的食物摄入量和体重。此外，瘦素和exenetrin联合给药可使血糖水平正常化，并伴有胰岛素敏感性的改善、葡萄糖刺激的胰岛素分泌的恢复、非脂肪组织中甘油三酯含量的正常化、血浆胰高血糖素水平的改善和胰腺胰岛素含量的恢复，而不是每种单药治疗。配对饲养实验表明，exenetrin通过独立的热量限制机制增强瘦素的效应。这些研究结果表明，瘦素和exenlavin的共同管理可能是一个有益的治疗肥胖2型糖尿病引起瘦素的影响。

Coadministration of leptin and exenatide significantly reduced food intake and body weight in obese type2 diabetic mice, compared with either monotherapy alone. Moreover, coadministration of leptin and exenatide normalized blood glucose levels accompanied by improvement of insulin sensitivity, restoration of glucose stimulated insulin secretion, normalization of triglyceride contents in non-adipose tissues, improvement of plasma glucagon levels and restoration of pancreatic insulin contents, while not each monotherapy. Pair-feeding experiments indicated that exenatide enhanced the leptin’s effects through independent mechanism of caloric restriction. These findings suggest that coadministration of leptin and exenatide could be a beneficial treatment for obese type2 diabetes by eliciting leptin’s effects.